U.S. markets close in 2 hours 32 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
524.99+8.37 (+1.62%)
As of 1:28PM EDT. Market open.
Sign in to post a message.
  • L
    Larry
    Is (REGN) going to $526.00 by Wednesday and $552.00 by Friday,?
  • 丞熹
    Really need to break $507 and stand firm. Then $526.4, $552.8, $616.7
    Since May is breaking the monthly M.A, hopefully June can take off. Then Technical support would be sufficient.
    And when next earning release, will have fundamental support.
    Bullish
  • R
    Ron
    There is clinical study that shows that mRNA vacines (Moderna / Pfizer) are little less effective against the B.1.617 (so called Indian variant). The B.1.617 also showed resistance against Elli Lilly's monoclonal antibody. The good news is that the B.1.617 was efficiently inhibited by the REGN-COV monoclonal antibody cocktail. Several EU countries saw the B.1.617 strain emerge lately and there is now also a medicine, the EMA just needs to approve it. WHO has flagged the B.1.617 as a variant of concern. This explains why Rohe obtained approval for the Regeneron product in India last week.
  • R
    Richard
    I want to see if @ItsJustMyOpinion buys when it closes above $520.
  • 丞熹
    As we can see, it keeps hitting $507-$508 for 7days within 2 weeks.
    Every time pull back in 2nd half of the trading day. So it's a super strong resistant.
    Knowing the overall mkt starts the down trend, every individual stock would have stress (including REGN)
    Won't be surprise to see it down again tomorrow.
    But if REGN doesn't pull back today, I will consider add more position.
    Bullish
  • E
    Ed
    The government has stopped shipment of Eli Lilly's antibody cocktail in Illinois because it is not effective against the P.1 Brazilian variant. REGN's cocktail retains is potency, however.
  • R
    Ron
    The numbers are out and the EPS blew far above the estimate.
    Now we are in good shape to break out higher and there is more good news in the pipe, they may share some of it during the call.
    Bullish
  • H
    Haskell
    The maximum pain theory of options seems to predict a price of about $500 by the end of the week. There are over 2000 put options at a strike of $500 so it won't go below that, but there are quite a few call options above $500 that the market makers will want to avoid paying on, so they will try to reduce the price to around this point. It's all about the market makers minimizing what they or their rich clients have to pay out. Hope I am wrong about this.
    Bullish
  • 丞熹
    Like I mention, if yesterday stay above $507, I will add more position.
    Might be some bad trading days to make it volatile. But Uptrend has started.
    Come on folks
  • M
    Mark
    Who thinks the stock reaches $550 by July 1st?
  • R
    Ron
    India approves Regeneron cocktail. With 1.3 billion inhabitants and 300K new cases a day, that is a big market, means whatever can be produced can be sold.
  • I
    ItsJustMyOpinion
    As I stated my buy points were $420 or $520. I am in again. Hope it works out better this time. My sell point is $550 with a stop sell at $480 again.
  • L
    Larry
    look like all of us can say goodbye to all the option premiums we paid for the $500.00 strike price If any one of us walked into a grocery store and took $100.00 worth of food and walked out without paying we all be charged with shoplifting, but it's okay for the big boys of wall street to help themself from our account? and this is what we call investing ?
  • p
    paolo
    $INO conversation
    ...after P2 datas result, maybe now is clear why $REGN it seems to be interested to buy INO at $30/share
  • B
    Bruce
  • c
    chris
    Regeneron has beaten analyst expectation by one dollar per share for the last 4/4 quarters. If that continues they will make $49-50 per share in 2021.
    Price to earnings of 10. Growth of 60% from last year.
    BUY BUY BUY!
    Bullish
  • R
    Robert
    I'm puzzled by the COV2 sales numbers in the Q1 Financial Results press release. In the "Revenues" paragraph near the beginning COV2 sales in the US were reported $262M in the table. In a paragraph after the table it was said that Roche collaboration contribution to sales was $67M. This is in agreement with Table 4 which lists all sources of collaboration revenue. So far so good. But then there's Table 5 summarizing all net product sales with a US sales column and a ROW (Rest of World) column. The US sales for COV2 in table 5 is $262M (same as mentioned earlier) but the ROW sales is $177M?? If Roche is ROW and was $67M where did the extra $110M ROW come from? I checked the 10-K filing on EDGAR and the same numbers are there. Clearly I'm missing something?? Any help would be appreciated. TIA
  • I
    InvestmentFreak
    REGN is significantly undervalued. This is my biggest holding and I continue to add as long as the stock is that cheap!
    Bullish
  • c
    chris
    Gonna fly with lower dose approval soon.
    Bullish
  • L
    Larry
    Looks like the boogeyman is on his way with a bag in his hand collecting all options premiums that we paid for the $510.00 strike price, I said it yesterday Churchill Swartz & Associate can pull a rabbit out of a hat, Bam, Bam, Booyah.